The short answer: Not through any approved route today. Retatrutide is still investigational, and Eli Lilly plans to file for FDA approval in the first quarter of 2027. No trial has tested a direct switch from tirzepatide, and the main Phase 3 trials excluded anyone who took a weight-loss drug in the 90 days before screening. Any retatrutide sold to the public now is unapproved, and federal law bars pharmacies from compounding it.

People ask this question because tirzepatide (Mounjaro, Zepbound) has stopped working as well for them, or because the retatrutide trial numbers look larger. Both are fair reasons to talk with a clinician. Neither one changes what is legal or what the evidence shows. For a side-by-side look at the two drugs themselves, see retatrutide vs tirzepatide. This article covers only the switch.

Is retatrutide approved yet?

No. In a September 29, 2026 release on detailed TRIUMPH-2 results, Lilly still called retatrutide "an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist." The same release said Lilly plans to submit a Biologics License Application to the FDA in Q1 2027 (Eli Lilly, September 29, 2026).

The July 23, 2026 topline release gave the reason for the gap. Lilly said it is still completing the chemistry, manufacturing, and controls data package that an application needs (Eli Lilly, July 23, 2026). A filing is not an approval. The FDA review comes after it. Our page on when retatrutide could be approved walks through that timeline.

So a prescriber cannot write a normal prescription for retatrutide in the United States today. There is no pharmacy product to fill.

Did trial participants switch from tirzepatide?

No. The trials were built to keep recent weight-loss drug users out. ClinicalTrials.gov lists the same exclusion for TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and TRIUMPH-4: people who "have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening" could not enroll (TRIUMPH-1, NCT05929066). Each trial also excluded people whose weight changed by more than 5 kg (11 pounds) in the 90 days before screening.

The registry entries do not name GLP-1 drugs or tirzepatide in that line. The wording covers any weight-loss drug. In practice, that would include tirzepatide used for weight. The earlier Phase 2 obesity trial used similar language. It excluded people using "medications that promote weight loss" (NCT04881760).

This matters for how you read the results. In TRIUMPH-1, the 12 mg group lost 25.0% of body weight at 80 weeks on the intention-to-treat analysis, versus 3.9% on placebo (Jastreboff et al., NEJM 2026). Those people started from a drug-free baseline. Nobody has published how much extra weight a person loses after moving from a tirzepatide plateau to retatrutide.

What will the TRIUMPH-5 head-to-head trial show?

TRIUMPH-5 compares retatrutide with tirzepatide directly in adults with obesity. Its registry entry lists about 800 participants and a primary outcome of percent change in body weight at week 80 (TRIUMPH-5, NCT06662383). As of its July 2026 update, the trial was active but not recruiting. Its estimated primary completion date is November 2026.

TRIUMPH-5 is not a switching study. It uses the same 90-day exclusion for weight-loss drugs. Participants start on one drug or the other. It will tell you which drug works better from the start. It will not tell you what happens when someone moves from one to the other.

Other ongoing trials do not answer the question either. TRIUMPH-6 tests how retatrutide maintains weight loss. All participants take retatrutide during an 80-week lead-in, then some move to a second dose or to placebo (TRIUMPH-6, NCT06859268). It also excludes recent weight-loss drug use.

How much do the two drugs overlap?

A lot. The Zepbound label describes tirzepatide as "a GIP receptor and GLP-1 receptor agonist" (Zepbound label, DailyMed). Retatrutide acts on those same two receptors and adds a third, the glucagon receptor (Jastreboff et al., NEJM 2023).

Two facts follow from that overlap:

  • Taking both is not a plan. The Zepbound label says coadministration "with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended." Retatrutide is a GLP-1 receptor agonist, so stacking the two would double up on the same target.
  • Tirzepatide does not leave your body right away. The label gives tirzepatide a half-life of about 5 days. Any drug a person starts soon after stopping it would overlap with what is still in circulation.

Because of this overlap, the gut side effects are similar too. In the Phase 2 trial, gastrointestinal events were the most common, rose with dose, and eased with a lower starting dose. No published data shows how those side effects behave when a person moves straight from tirzepatide. That is one more reason this is a question for a clinician, not a forum.

Why is switching outside a trial risky?

Any retatrutide you can buy today is unapproved. The FDA states that "retatrutide and cagrilintide cannot be used in compounding under federal law." It adds that they "have not been found safe and effective for any condition" (FDA, Concerns with Unapproved GLP-1 Drugs).

The FDA has warned telehealth companies for marketing unapproved drugs such as retatrutide. It has also warned sellers of retatrutide labeled "for research purposes" or "not for human consumption" that was sold to consumers with dosing instructions. The agency says products like these may be counterfeit. They could also hold the wrong ingredient, or too much, too little, or none of the active drug.

That last point is the core problem with a self-directed switch. You would move from a drug with a known dose and an FDA label to a vial of unknown content. Our page on gray-market retatrutide covers the testing and contamination issues in more detail.

There are three routes, and none of them is a home switch:

  1. Talk with your prescriber about your current plan. A plateau on tirzepatide is common. Your clinician can review your dose, side effects, other medicines, and options that are already approved.
  2. Look for a clinical trial. ClinicalTrials.gov lists several retatrutide studies. Most exclude people who used a weight-loss drug in the prior 90 days, so screening rules matter. A trial site can tell you if you qualify.
  3. Ask about expanded access. In June 2026, Lilly posted a pre-approval expanded access program for single patients (NCT07629401). It is narrow. It covers adults with a BMI of 35 or higher despite the highest available dose of an approved weight-management drug, plus two or more serious obesity-related conditions. The person must also be unable to join a retatrutide trial. Requests come from the treating physician, not the patient.

For more on tirzepatide itself, including dose steps and side effects, see mounjaro.md.

The bottom line

You cannot legally switch from tirzepatide to retatrutide at a pharmacy today, because retatrutide is not approved. Lilly plans to file in Q1 2027. The Phase 3 trials excluded people who used a weight-loss drug in the prior 90 days, so there is no data on a direct switch. The two drugs share the GIP and GLP-1 receptors, and the Zepbound label advises against combining tirzepatide with any GLP-1 receptor agonist. If tirzepatide has stalled for you, a clinician, a trial site, or the expanded access route are the safe paths. A gray-market vial is not.

Last updated: October 2026. This article is for informational purposes only and does not constitute medical advice. Do not stop, start, or change a weight-loss medicine without talking to your prescriber.